CATX Notícias Forex
Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers
Radiopharmaceutical company Perspective Therapeutics, Inc. (CATX) announced Tuesday a clinical trial collaboration agreement with Bristol Myers Squibb Co. (BMY) to evaluate the safety and tolerability of Perspective's targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristol Myers Squibb's nivolumab in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans.
RTTNews
|
234 dias atrás
